Curriculum vitae

PERSONAL INFORMATION Katerina Kopeckova

WORK EXPERIENCE

September 1997–February 2002 PhysicianUniversity Hospital Motol Prague (Czech Republic)

Dept. of Oncology and Radiotherapy

August 2002–December 2002 Registrare jr. Kuwait Cancer Centre (Kuwait)

Dept. of Oncology

February 2003–Present Senior physician University Hospital Motol Prague (Czech Republic)

Medical Oncologist

EDUCATION AND TRAINING

September 1982–May 1988 Medical doctorCharles University Plzen (Czech Republic)

General medicine

1991–1991 Postgraduate degree in internal medicineCharles University- Universtity Hospital Plzen (Czech Republic)

May 1997–May 1997 Postgraduate in medical oncologyCharles University Prague (Czech Republic)

ADDITIONAL INFORMATION

Expertise Medical oncology- solid tumours- breast, colorectal cancer, sarcoma

- non- hodgkins lymphoma

- anticancer immunotherapy

Pharmacoeconomics

Publications [1] PYTLIK, Robert, David BELADA, Katerina KUBACKOVA, Ingrid VASOVA, Tomas KOZAK, Jan PIRNOS, Ingrid BOLOMSKA, Milan MATUSKA, Jana PRIBYLOVA, Vit CAMPR, Lucie BURESOVA, Alice SYKOROVA, Adela BERKOVA, Pavel KLENER, Marek TRNENY a Czech Lymphoma Study GRP. Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial. LEUKEMIA & LYMPHOMA [online]. 2015, roč. 56, č. 1, s. 57–64. ISSN 1042-8194. Dostupné z: doi:10.3109/10428194.2014.904509

IF13 = 2.605

[2] POPRACH, Alexandr, Zbynek BORTLICEK, Bohuslav MELICHAR, Radek LAKOMY, Marek SVOBODA, Igor KISS, Milada ZEMANOVA, Ondrej FIALA, Katerina KUBACKOVA, Oldrich COUFAL,Tomas PAVLIK, Ladislav DUSEK, Rostislav VYZULA a Tomas BUCHLER. Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency. EUROPEAN JOURNAL OF CANCER [online]. 2015, roč. 51, č. 4, s. 507–513. ISSN 0959-8049. Dostupné z: doi:10.1016/j.ejca.2014.12.010

25/6/18 © European Union, 2002-2018 | http://europass.cedefop.europa.eu Page 1 / 4

Curriculum vitae Katerina Kopeckova

IF13 = 4.819

[3] KUBACKOVA, Katerina, Zbynek BORTLICEK, Tomas PIKUS, Zdenek LINKE, Petra POKORNA, Rostislav VYZULA a Jana PRAUSOVA. Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data. FUTURE ONCOLOGY [online]. 2015, roč. 11, č. 2, s. 225–232. ISSN 1479-6694. Dostupné z: doi:10.2217/FON.14.240

IF13 = 2.611

[4] POPRACH, Alexandr, Tomas PAVLIK, Bohuslav MELICHAR, Katerina KUBACKOVA, Zbynek BORTLICEK, Marek SVOBODA, Radek LAKOMY, Rostislav VYZULA, Igor KISS, Ladislav DUSEK, Tomas BUCHLER a Czech Renal Canc Cooperative GRP. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS [online]. 2014, roč. 32, č. 4, s. 488–495. ISSN 1078-1439. Dostupné z: doi:10.1016/j.urolonc.2013.09.011

IF13 = 3.363

[5] KUNICKA, Tereza, Radka VACLAVIKOVA, Viktor HLAVAC, David VRANA, Vaclav PECHA, Karel RAUS, Marketa TRNKOVA, Katerina KUBACKOVA, Miloslav AMBRUS, Ludmila VODICKOVA, PavelVODICKA a Pavel SOUCEK. Non-Coding Polymorphisms in Nucleotide Binding Domain 1 in ABCC1 Gene Associate with Transcript Level and Survival of Patients with Breast Cancer. PLOS ONE [online]. 2014, roč. 9, č. 7. ISSN 1932-6203. Dostupné z: doi:10.1371/journal.pone.0101740

IF13 = 3.534

[6] HLAVAC, Viktor, Veronika BRYNYCHOVA, Radka VACLAVIKOVA, Marie EHRLICHOVA, David VRANA, Vaclav PECHA, Marketa TRNKOVA, Roman KODET, Marcela MRHALOVA, Katerina KUBACKOVA, Jiri GATEK, Petr VAZAN a Pavel SOUCEK. The Role of Cytochromes P450 and Aldo-Keto Reductases in Prognosis of Breast Carcinoma Patients. MEDICINE [online]. 2014, roč. 93, č. 28.ISSN 0025-7974. Dostupné z: doi:10.1097/MD.0000000000000255

IF13 = 4.867

[7] BUCHLER, Tomas, Zbynek BORTLICEK, Alexandr POPRACH, Katerina KUBACKOVA, Igor KISS, Milada ZEMANOVA, Ondrej FIALA, Ladislav DUSEK, Rostislav VYZULA, Bohuslav MELICHAR a Czech Renal Canc Cooperative GRP. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS [online]. 2014, roč. 32, č. 5, s. 569–575. ISSN 1078-1439. Dostupné z: doi:10.1016/j.urolonc.2013.12.007

IF13 = 3.363

[8] PRAUSOVA, J., K. KUBACKOVA, L. DUSEK, S. VINAKURAU, T. PIKUS, B. MALINOVA, J. HOCH, R. KODET a Z. LINKE. Influence of neoadjuvant treatment of rectal carcinoma on operability and incidence of distant metastases. BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY [online]. 2013, roč. 114, č. 8, s. 469–473. ISSN 0006-9248. Dostupné z: doi:10.4149/BLL_2013_098

IF13 = 0.446

[9] DAVIES, Christina, Hongchao PAN, Jon GODWIN, Richard GRAY, Rodrigo ARRIAGADA, Vinod RAINA, Mirta ABRAHAM, Victor Hugo MEDEIROS ALENCAR, Atef BADRAN, Xavier BONFILL, Joan BRADBURY, Michael CLARKE, Rory COLLINS, Susan R. DAVIS, Antonella DELMESTRI, JohnF. FORBES, Peiman HADDAD, Ming-Feng HOU, Moshe INBAR, Hussein KHALED, Joanna KIELANOWSKA, Wing-Hong KWAN, Beela S. MATHEW, Indraneel MITTRA, Bettina MUELLER, Antonio NICOLUCCI, Octavio PERALTA, Fany PERNAS, Lubos PETRUZELKA, Tadeusz PIENKOWSKI, Ramachandran RADHIKA, Balakrishnan RAJAN, Maryna T. RUBACH, Sera TORT, Gerard URRUTIA, Miriam VALENTINI, Yaochen WANG, Richard PETO a Adjuvant Tamoxifen LongerAGAINST. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. LANCET [online]. 2013, roč. 381, č. 9869, s. 805–816. ISSN 0140-6736. Dostupné z: doi:10.1016/S0140-6736(12)61963-1

IF13 = 39.207

[10] BRYNYCHOVA, Veronika, Viktor HLAVAC, Marie EHRLICHOVA, Radka VACLAVIKOVA, Vaclav PECHA, Marketa TRNKOVA, Martin WALD, Marcela MRHALOVA, Katerina KUBACKOVA, Tomas PIKUS, Roman KODET, Jan KOVAR a Pavel SOUCEK. Importance of transcript levels of caspase-2 isoforms S and L for breast carcinoma progression. FUTURE ONCOLOGY [online]. 2013, roč. 9, č. 3, s. 427–438. ISSN 1479-6694. Dostupné z: doi:10.2217/FON.12.200

IF13 = 2.611

[11] HUBACKOVA, Miluse, Radka VACLAVIKOVA, Marie EHRLICHOVA, Marcela MRHALOVA, Roman KODET, Katerina KUBACKOVA, David VRANA, Ivan GUT a Pavel SOUCEK. Association of

25/6/18 © European Union, 2002-2018 | http://europass.cedefop.europa.eu Page 2 / 4

Curriculum vitae Katerina Kopeckova

superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas. INTERNATIONAL JOURNAL OF CANCER [online]. 2012, roč. 130, č. 2, s. 338–348. ISSN 0020-7136. Dostupné z: doi:10.1002/ijc.26006

IF12 = 6.198

[12] WESTERMARK, Kerstin, Birthe Byskov HOLM, Mirjam SODERHOLM, Jordi LLINARES-GARCIA, Frida RIVIERE, Stiina AARUM, Florence BUTLEN-DUCUING, Stelios TSIGKOS, Agnieszka WILK-KACHLICKA, Cinzia N’DIAMOI, Comm Orphan Med PROD a European Med AGCY. European regulation on orphan medicinal products: 10 years of experience and future perspectives. NATURE REVIEWS DRUG DISCOVERY [online]. 2011, roč. 10, č. 5, s. 341–349. ISSN1474-1776. Dostupné z: doi:10.1038/nrd3445

IF11 = 29.008

[13] PFREUNDSCHUH, Michael, Evelyn KUHNT, Lorenz TRUEMPER, Anders OSTERBORG, Marek TRNENY, Lois SHEPHERD, Devinder S. GILL, Jan WALEWSKI, Ruth PETTENGELL, Ulrich JAEGER, Pier-Luigi ZINZANI, Ofer SHPILBERG, Stein KVALOY, Peter de Nully BROWN, Rolf STAHEL, Noel MILPIED, Armando LOPEZ-GUILLERMO, Viola POESCHEL, Sandra GRASS, Markus LOEFFLER, Niels MURAWSKI a MabThera Int Trial MinT GRP. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. LANCETONCOLOGY [online]. 2011, roč. 12, č. 11, s. 1013–1022. ISSN 1470-2045. Dostupné z: doi:10.1016/S1470-2045(11)70235-2

IF11 = 22.589

[14] VOTAVOVA, H., K. FORSTEROVA, V. CAMPR, J. SRITESKY, Z. VELENSKA, R. PYTLIK, K. KUBACKOVA, B. PROCHAZKA, R. KODET, I. SPICKA, H. KREJCOVA, M. TRNENY a P. KLENER. Distinguishing of primary mediastinal B-cell lymphoma and diffuse large B-cell lymphoma using real-time quantitative polymerase chain reaction. NEOPLASMA [online]. 2010, roč. 57, č. 5, s. 449–454. ISSN 0028-2685. Dostupné z: doi:10.4149/neo_2010_05_449

IF10 = 1.449

[15] HUBACKOVA, Miluse, Radka VACLAVIKOVA, Marcela MRHALOVA, Katerina KUBACKOVA, Roman KODET, Ivan GUT a Pavel SOUCEK. NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico-pathological characteristcs of human mammary tumors. PHARMACOGENETICS AND GENOMICS [online]. 2009, roč. 19, č. 7, s. 505–512. ISSN 1744-6872. Dostupné z: doi:10.1097/FPC.0b013e32832cf9cf

IF09 = 3.991

[16] PRAUSOVA, J., T. ECKSCHLAGER, M. MRHALOVA, A. SLOBODNIK, K. KUBACKOVA, S. VINAKURAU a R. KODET. Clinical, pathological and molecular characteristics of newly diagnosed breast. NEOPLASMA. 2007, roč. 54, č. 5, s. 407–412. ISSN 0028-2685.

IF07 = 1.208

[17] PRAUSOVA, J, R LOHYNSKA, K KUBACKOVA, Z LINKE, B MALINOVA, E KUBALA a J NOVOTNY. Preoperative radiotherapy for locally advanced rectal cancer and prognostic factors influencing outcome. NEOPLASMA. 2006, roč. 53, č. 3, s. 263–268. ISSN 0028-2685.

IF06 = 1.247

[18] RIHOVA, B, J STROHALM, M KOVAR, T MRKVAN, V SUBR, O HOVORKA, M SIROVA, L ROZPRIMOVA, K KUBACKOVA a K ULBRICH. Induction of systemic antitumour resistance with targeted polymers. SCANDINAVIAN JOURNAL OF IMMUNOLOGY [online]. 2005, roč. 62, č. 1, s. 100–105. ISSN 0300-9475. Dostupné z: doi:10.1111/j.1365-3083.2005.01617.x

IF05 = 2.023

[19] RIHOVA, B, J STROHALM, J PRAUSOVA, K KUBACKOVA, M JELINKOVA, L ROZPRIMOVA, M SIROVA, D PLOCOVA, T ETRYCH, V SUBR, T MRKVAN, M KOVAR a K ULBRICH. Cytotoxic and immunomodulatory activites of polymer-bound drugs. In: THOMAS, DW, ed. ADVANCED BIOMATERIALS FOR MEDICAL APPLICATIONS. PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS: SPRINGER, 2004, s. 67–78. NATO Science Series II-Mathematics Physics and Chemistry. ISBN 1-4020-2906-3.

IF04 = nemá IF

[20] RIHOVA, B, J STROHALM, J PRAUSOVA, K KUBACKOVA, M JELINKOVA, L ROZPRIMOVA, M SIROVA, D PLOCOVA, T ETRYCH, V SUBR, T MRKVAN, M KOVAR a K ULBRICH. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. JOURNAL OF CONTROLLED RELEASE [online]. 2003, roč. 91, č. 1-2, SI, s. 1–16. ISSN 0168-3659.Dostupné z: doi:10.1016/S0168-3659(03)00235-9

25/6/18 © European Union, 2002-2018 | http://europass.cedefop.europa.eu Page 3 / 4

Curriculum vitae Katerina Kopeckova

IF03 = 3.298

[21] RIHOVA, B, J STROHALM, K KUBACKOVA, M JELINKOVA, L ROZPRIMOVA, M SIROVA, D PLOCOVA, T MRKVAN, M KOVAR, J POKORNA, T ETRYCH a K ULBRICH. Drug-HPMA-HuIg conjugates effective against human solid cancer. In: MAEDA, H AND KABANOV, A AND KATAOKA, K AND OKANO, T, ed. POLYMER DRUGS IN THE CLINICAL STAGE: ADVANTAGES AND PROSPECTS. 233 SPRING ST, NEW YORK, NY 10013 USA: KLUWER ACADEMIC/PLENUM PUBL, 2003, s. 125–143. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. ISBN 0-306-47471-9.

IF03 = nemá IF

[22] RIHOVA, B, J STROHALM, K KUBACKOVA, M JELINKOVA, O HOVORKA, M KOVAR, D PLOCOVA, M SIROVA, M ST’ASTNY, L ROZPRIMOVA a K ULBRICH. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs. JOURNAL OF CONTROLLED RELEASE [online]. 2002, roč. 78, č. 1-3, s. 97–114. ISSN 0168-3659. Dostupné z: doi:10.1016/S0168-3659(01)00489-8

IF02 = 3.131

Projects Cost- of illness- RCC - Masaryk University Brno - start September 20013

Memberships ESMO,

EORTC

Czech Cancer Society

Other Relevant Information Ministry of Health CZ- Working group for rare diseases, member of the expert group of EC for Eureropean reference network

25/6/18 © European Union, 2002-2018 | http://europass.cedefop.europa.eu Page 4 / 4